The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women

Addo, Rebecca; Haas, Marion; Goodall, Stephen

doi:10.1016/j.vhri.2021.05.005

Cited by 7 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using a ow cytometry kit, propidium iodide (PI) (ab139418, Abcam), cell cycle arrest and distribution were carried out. This kit was intended to measure the quantity of DNA in cultured cells because 5 × 10 5 cells were grown both with and without the test substance (2). Aer being rinsed with 100 mL of PBS and stained at room temperature with a staining solution of RNase (200 L) and PI, the adhering cells were xed in ethanol (70%) for two hours at 4 °C and kept in the dark for 15 min.…”

Section: Methodsmentioning

confidence: 99%

“…1 Numerous studies have shown how the development of BC depends on hormones and how effective hormone antagonists are. 2,3 Although estrogen receptor (ER)-positive cancers are still best managed by hormone therapy, this form of treatment efficacy is severely constrained by developed endocrine resistance. [4][5][6] Additionally, in triple-negative breast cancer (TNBC), where the ER and human epidermal growth factor receptor-2 (HER2) targets are inactive, it loses its efficacy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New cyclic glycolipids from Silene succulenta promote in vitro MCF-7 breast carcinoma cell apoptosis by cell cycle arrest and in silico mitotic Mps1/TTK inhibition

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

New cyclic glycolipids from Silene succulenta promote in vitro MCF-7 breast carcinoma cell apoptosis by cell cycle arrest and in silico mitotic Mps1/TTK inhibition

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For example, in the study by Dong et al [ 25 ], grade 3 or 4 AEs with an incidence rate > 5% or significant differences between the two strategies were included in the model. Addo et al [ 26 ] restricted AEs to vaginal bleeding, musculoskeletal disorders such as arthralgia, deep vein thrombosis, and pulmonary embolism according to expert opinions.…”

Section: Resultsmentioning

confidence: 99%

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

Dai

Chang

et al. 2023

PharmacoEconomics

View full text Add to dashboard Cite

Background The disutilities of adverse events (AEs) are important inputs for cost-utility analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology assessment institutions and scholars have proposed recommendations for applying disutility values in economic evaluations. Objectives This study aimed to identify the current use of disutilities of AEs as model parameters in the CUA of cancer drug therapy and to compare the discrepancies between the use of disutilities and published recommendations. Methods A systematic search was conducted on the PubMed, Web of Science, and Cochrane Library databases, as well as the official websites of the National Institute for Health and Care Research (NIHR), the Institute for Clinical and Economic Review (ICER), the Institute for Quality and Efficiency in Health Care (IQWiG), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Centre for Reviews and Dissemination (CRD) for CUAs of drug therapy for cancer published in English from January 2019 to April 2022. Information about the use of disutilities of AEs (whether and how disutilities were used, or why they were not used) in selected studies was extracted and compared with published recommendations. Descriptive analyses were used to summarize the results. Results A total of 467 CUAs were included, 54% (254/467) of which included disutilities of AEs in their model. The proportion that included these disutilities increased from 2019 to 2021, ranging from 47% (51/107) to 61% (116/190). Only 6% (15/254) of the CUAs using disutilities of AEs considered all five recommendations about the justification for inclusion and exclusion, description of values and sources, grades of AEs, calculation, and uncertainty analyses. Only 15% (72/467) provided a clear justification for inclusion and exclusion of disutilities of AEs, and 7% (17/254) did not provide values or sources. In total, 69% (175/254) of the analyses focused on AEs of grade 3 or greater, and 11% (28/254) applied utility decrements for grades 1 and 2. Disutilities of AEs were generally calculated using the incidence rates, which were clearly stated in 49% (65/132) of the analyses. Uncertainty analyses were conducted in 84% (214/254) of the CUAs. Conclusions The current use of disutilities of AEs in CUAs shows some discrepancies with recommendations proposed in the literature. One is that detailed information about the use of disutilities of AEs was not reported and the other is that essential methods to analyze the impact of AEs on quality-adjusted life-years were not thoroughly conducted. Therefore, it is suggested that researchers should attach importance to the impact of AEs on health-related quality of life. Furthermore, an application process was developed for the disutilities of AEs to remind and guide researchers to correctly use the disutilities of AEs as parameters in the decision-analytic model...

show abstract

Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta‐analysis

Elshafie,

Trivedi,

Villa‐Zapata

et al. 2024

Cancer

View full text Add to dashboard Cite

BackgroundDespite significant advances in breast cancer control and survival with endocrine therapies (ETs), treatment utilization and outcomes in developing countries have not been adequately explored. This review evaluated ET adherence, potential benefits, and harms in populations across developing countries.MethodsA literature search was conducted through August 2023 in five databases: PubMed, Cochrane Library, Web of Science, Global Health, and WHO Global Index Medicus. Retrieved records were screened to identify observational research presenting at least one outcome in women with nonmetastatic breast cancer in developing countries who received ET (tamoxifen or aromatase inhibitors). A random effects model was used to compute the rates of adherence, discontinuation, adverse events (AEs), disease progression, and death.ResultsA total of 104 studies met the inclusion criteria. Risk of bias was low in most studies, and a large portion of the patients involved Asians. The overall heterogeneity between studies was partially attributed to variations in study design or outcome measurement method. Results showed a pooled adherence rate of 75% (95% confidence interval [CI], 67%–81%) and a discontinuation rate of 16% (95% CI, 10%–25%). Treatment side effects and young age consistently emerged as significant predictors of nonadherence. A wide range of AEs was identified in our analysis. The estimated average rates of cancer recurrence and mortality at 5‐years were 16% and 8%, respectively.ConclusionsThe findings of this study underscore suboptimal ET use in developing countries and provide comprehensive insights into treatment experiences in the real‐world setting. Targeted strategies are warranted to enhance adherence and subsequently optimize treatment benefits.

show abstract

The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women

Cited by 7 publications

References 35 publications

New cyclic glycolipids from Silene succulenta promote in vitro MCF-7 breast carcinoma cell apoptosis by cell cycle arrest and in silico mitotic Mps1/TTK inhibition

New cyclic glycolipids from Silene succulenta promote in vitro MCF-7 breast carcinoma cell apoptosis by cell cycle arrest and in silico mitotic Mps1/TTK inhibition

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta‐analysis

Contact Info

Product

Resources

About